At the conference, which takes place at the Encore Hotel in Las Vegas, Scott Powell, chief financial officer of Volition America, will provide an update about the company’s key business, clinical, regulatory and operational achievements.
Earlier this year, VolitionRx hailed positive interim results from its huge trial in Denmark concerning colorectal cancer (CRC), which point to being able to detect early signs of the disease.
The ongoing study is in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program.
Meanwhile, in the US, VolitionRx is taking part in what is believed to be the largest ever colorectal cancer screening study in collaboration with the National Cancer Institute's Early Detection Research Network with a cohort of over 13,500 subjects.
Collection is underway and is expected to be completed in 2020.
In early trade, shares of VolitionRx were 2.9% higher at US$2.15.